StockNews.AI
SYRS
StockNews.AI
172 days

Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration

1. Syros Pharmaceuticals plans to delist from Nasdaq and deregister its common stock.

2m saved
Insight
Article

FAQ

Why Very Bearish?

Delisting typically signals reduced investor interest and potential financial instability, impacting stock value negatively. Historical examples indicate significant price drops for stocks that delist.

How important is it?

Delisting and deregistration significantly hinder stock’s liquidity and transparency, strongly impacting investor sentiment and perceived value.

Why Short Term?

Immediate negative sentiment from delisting may lead to price volatility and investor exit. Historical stocks faced similar immediate impacts post-delisting.

Related Companies

NASDAQ
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the “Company”) today announced that its Board of Directors (the “Board”) has approved and the Company intends to proceed with the voluntary delisting of its common stock from the Nasdaq Stock Market (“Nasdaq”) and the deregistration of its common stock in order to terminate and suspend the Company's reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"). The Company today.

Related News